AR033796A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR033796A1
AR033796A1 ARP000103325A ARP000103325A AR033796A1 AR 033796 A1 AR033796 A1 AR 033796A1 AR P000103325 A ARP000103325 A AR P000103325A AR P000103325 A ARP000103325 A AR P000103325A AR 033796 A1 AR033796 A1 AR 033796A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
entacapone
carbidopa
levodopa
sugar
Prior art date
Application number
ARP000103325A
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR033796A1 publication Critical patent/AR033796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Una composición farmacéutica, en especial con una composición sólida oral, que comprende cantidades farmacéuticamente efectivas de entacapone, levodopa y carbidopa o de sus sales o hidratos farmacéuticamente aceptables y un excipiente farmacéuticamente aceptable, en donde el excipiente es un alcohol de azúcar o almidón o un alcohol de azúcar y almidón. El entacapone, la levodopa y la carbidopa son útiles para tratar el mal de Parkinson
ARP000103325A 1999-06-30 2000-06-29 Composicion farmaceutica AR033796A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
AR033796A1 true AR033796A1 (es) 2004-01-07

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103325A AR033796A1 (es) 1999-06-30 2000-06-29 Composicion farmaceutica

Country Status (42)

Country Link
US (2) US6500867B1 (es)
EP (1) EP1189608B1 (es)
JP (2) JP4204783B2 (es)
KR (1) KR100905428B1 (es)
CN (1) CN1168440C (es)
AR (1) AR033796A1 (es)
AT (1) ATE245417T1 (es)
AU (1) AU765932B2 (es)
BG (1) BG65364B1 (es)
BR (2) BRPI0011867B8 (es)
CA (1) CA2378469C (es)
CO (1) CO5180579A1 (es)
CZ (2) CZ304416B6 (es)
DE (1) DE60004052T2 (es)
DK (1) DK1189608T3 (es)
EA (1) EA004503B1 (es)
EE (1) EE05473B1 (es)
ES (1) ES2203495T3 (es)
FI (1) FI109453B (es)
FR (1) FR2797587A1 (es)
GE (1) GEP20043314B (es)
HK (1) HK1047040B (es)
HR (1) HRP20020088B1 (es)
HU (1) HU230395B1 (es)
IL (1) IL146807A (es)
IT (1) ITMI20001450A1 (es)
ME (1) ME00520B (es)
MX (1) MXPA01013167A (es)
MY (1) MY127685A (es)
NO (2) NO330260B1 (es)
NZ (1) NZ515780A (es)
PE (1) PE20010399A1 (es)
PL (1) PL197818B1 (es)
PT (1) PT1189608E (es)
RS (1) RS50368B (es)
SI (1) SI1189608T1 (es)
SK (1) SK286451B6 (es)
TR (1) TR200103763T2 (es)
TW (1) TWI241187B (es)
UA (1) UA75047C2 (es)
WO (1) WO2001001984A1 (es)
ZA (1) ZA200109868B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
EP1560569A4 (en) * 2002-10-11 2006-03-22 Depomed Dev Ltd GASTRORETENTIVE LEVODOPA DELIVERY FORM
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
US20080187590A1 (en) 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US8772346B2 (en) * 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
RU2518483C2 (ru) 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Режим дозирования ингибиторов комт
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
US8728517B2 (en) * 2008-02-06 2014-05-20 Wockhardt Ltd. Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
CN102170870A (zh) * 2008-08-22 2011-08-31 沃克哈特研究中心 恩他卡朋或其盐的缓释药物组合物
NZ591328A (en) * 2008-08-22 2012-11-30 Wockhardt Research Center Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
BRPI1014865B1 (pt) 2009-04-01 2020-03-17 Bial - Portela & C.A., S.A. Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica
KR101709904B1 (ko) * 2009-05-19 2017-02-23 뉴로덤 엘티디 Dopa 데카르복실라제 억제제의 연속투여용 조성물
US9750702B2 (en) 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
BR112013011685B1 (pt) * 2010-11-15 2022-03-03 Neuroderm Ltd Composição líquida farmaceuticamente aceitável e emplastro transdérmico
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
US20140120166A1 (en) * 2011-04-26 2014-05-01 Innopharmax, Inc. Composition of entacopone
SI2791134T1 (sl) 2011-12-13 2020-01-31 Bial - Portela & Ca S.A. Kemična spojina, ki je uporabna kot vmesna oblika za pripravo inhibitorja katehol-o-metiltransferaze
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
ES2715028T3 (es) 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3116475T3 (pl) 2014-03-13 2021-02-08 Neuroderm Ltd Kompozycje inhibitora dekarboksylazy dopa
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EA036784B1 (ru) 2016-08-18 2020-12-21 Илько Илач Санайи Ве Тиджарет Аноним Ширкети Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
GEP20043314B (en) 2004-02-10
HUP0202273A3 (en) 2002-11-28
FR2797587A1 (fr) 2001-02-23
JP4204783B2 (ja) 2009-01-07
PL197818B1 (pl) 2008-04-30
NO20016203D0 (no) 2001-12-18
NO20016203L (no) 2002-02-25
PL352775A1 (en) 2003-09-08
YU92501A (sh) 2004-09-03
CN1168440C (zh) 2004-09-29
RS50368B (sr) 2009-11-10
CN1358090A (zh) 2002-07-10
MY127685A (en) 2006-12-29
HRP20020088B1 (en) 2007-05-31
CZ20014636A3 (cs) 2002-05-15
EP1189608B1 (en) 2003-07-23
FI991485A0 (fi) 1999-06-30
SK286451B6 (sk) 2008-10-07
US6797732B2 (en) 2004-09-28
EE200100716A (et) 2003-02-17
HRP20020088A2 (en) 2005-10-31
JP2008156373A (ja) 2008-07-10
HUP0202273A2 (en) 2002-10-28
DE60004052T2 (de) 2004-04-15
AU765932B2 (en) 2003-10-02
BRPI0011867B1 (pt) 2019-01-08
IL146807A (en) 2006-10-05
AU5830600A (en) 2001-01-22
SI1189608T1 (en) 2004-04-30
UA75047C2 (en) 2006-03-15
CZ304416B6 (cs) 2014-04-23
CZ303010B6 (cs) 2012-02-29
ES2203495T3 (es) 2004-04-16
WO2001001984A1 (en) 2001-01-11
DE60004052D1 (de) 2003-08-28
BG65364B1 (bg) 2008-04-30
ITMI20001450A1 (it) 2001-12-28
BR0011867A (pt) 2002-03-05
ATE245417T1 (de) 2003-08-15
PT1189608E (pt) 2003-12-31
CA2378469C (en) 2009-10-06
CA2378469A1 (en) 2001-01-11
EE05473B1 (et) 2011-10-17
KR20020010155A (ko) 2002-02-02
TWI241187B (en) 2005-10-11
EA200200106A1 (ru) 2002-06-27
FI109453B (fi) 2002-08-15
MXPA01013167A (es) 2002-07-02
JP4885896B2 (ja) 2012-02-29
US20030017201A1 (en) 2003-01-23
PE20010399A1 (es) 2001-04-10
ME00520B (me) 2011-10-10
TR200103763T2 (tr) 2002-04-22
EP1189608A1 (en) 2002-03-27
CO5180579A1 (es) 2002-07-30
US6500867B1 (en) 2002-12-31
NZ515780A (en) 2004-06-25
SK19232001A3 (sk) 2002-06-04
ZA200109868B (en) 2003-05-28
FI991485A (fi) 2000-12-31
HK1047040A1 (en) 2003-02-07
NO20110090L (no) 2002-02-25
EA004503B1 (ru) 2004-04-29
HU230395B1 (hu) 2016-04-28
DK1189608T3 (da) 2003-11-10
NO330260B1 (no) 2011-03-14
BRPI0011867B8 (pt) 2021-05-25
JP2003503454A (ja) 2003-01-28
HK1047040B (zh) 2005-04-29
KR100905428B1 (ko) 2009-06-30
ITMI20001450A0 (it) 2000-06-28
BG106251A (en) 2002-08-30

Similar Documents

Publication Publication Date Title
AR033796A1 (es) Composicion farmaceutica
MX9206851A (es) Sales organicas de n,n'-diacetil cistina, proceso para su preparacion y composicion farmaceutica que las contiene.
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
ES2109832T3 (es) Composicion dermatologica o farmaceutica, procedimiento de preparacion y utilizacion
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
DE69925133D1 (de) Pyrrolobenzodiazepine
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
IT1312377B1 (it) Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
BR9912010A (pt) Polimorfo de um produto farmacêutico
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ECSP003546A (es) Una nueva composicion farmaceutica
ES2117475T3 (es) Utilizacion de acidos monocarboxilicos para el tratamiento de materias queratinicas.